• 1
    Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427428.
  • 2
    Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429431.
  • 3
    Scorsone KA, Zhou YZ, Butel JS, Slagle BL. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 1992; 52: 16351638.
  • 4
    Li D, Cao Y, He L, Wang NJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 1993; 14: 169173.
  • 5
    Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 48554878.
  • 6
    Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994; 264: 13171319.
  • 7
    Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of GT in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993; 90: 85868590.
  • 8
    Harris CC. Structure and function of the tumor suppressor gene: clues for rational cancer therapeutic strategies. J Nat Cane Inst, in press.
  • 9
    Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957967.
  • 10
    Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci U S A 1991; 88: 80398043.
  • 11
    Macri P, Gordon JW. Delayed morbidity and mortality of albumin/SV40 T-antigen transgenic mice after insertion of an alpha-fetoprotein/herpes virus thymidine kinase transgene and treatment with ganciclovir. Hum Gene Ther 1994; 5: 175182.
  • 12
    Watanabe K, Saito A, Tamaoki T. Cell-specific enhancer activity in a far upstream region of the human alpha-fetoprotein gene. J Biol Chem 1987; 262: 48124818.
  • 13
    Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912915.
  • 14
    Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827830.
  • 15
    Morgenstern J, Land H. Choice and manipulation of retroviral vectors. In: MurrayEJ, ed. Methods in molecular biology. Clifton, NJ: Humana, 1991: 181202.
  • 16
    Sambrook J, Fritsch EF, Maniatis T. Molecular cloning, a laboratory manual. Vol II. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
  • 17
    Wang NP, To H, Lee WH, Lee EY. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 1993; 8: 279288.
  • 18
    Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, et al. The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996; 10: 12191232.
  • 19
    Gilboa E. Retrovirus vectors and their uses in molecular biology. Bioessays 1986; 5: 252257.
  • 20
    Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 22872291.
  • 21
    Friedmann T. Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 1992; 70: 18101817.
  • 22
    Zhang WW, Fang X, Mazur W, French BA, Georges, R., Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 513.
  • 23
    Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Dayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 36623667.
  • 24
    Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 16.
  • 25
    Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53: 41294133.
  • 26
    Bacchetti S, Graham F. Inhibition of cell proliferation by an adenovirus vector expressing the human wild-type p53 protein. Int J Oncol 1993; 3: 781788.
  • 27
    Sakai M, Morinaga T, Urano Y, Watanabe K, Wegmann TG, Tamaoki T. The human alpha-fetoprotein gene. Sequence organization and the 5′ flanking region. J Biol Chem 1985; 260: 50555060.
  • 28
    Sun T, Yu H, Hsai C, Wang N, Huang X. Evaluation of sera-survey trials for the early detection of hepatocellular carcinoma in areas of high prevalence. In: ChamberlainJ, MillerAB, eds. Screening for Gastrointestinal Cancer. Toronto, Lewiston, NY: Huber, 1988: 8186.
  • 29
    Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 15501552.
  • 30
    Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, Harris CC. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993; 14: 987992.